Follow us...


Search News Archives

News Channels


Coronavirus (COVID-19)


View Channel

New Laboratory Products


View Channel

Lab News


View Channel

Research & Case Studies


View Channel

Microscopy | Image Analysis


View Channel

Separation Science


View Channel



View Channel

Events | Webinars


View Channel

Conferences | Events

Sinensis Life Sciences Acquires Spinnovation

publication date: Oct 14, 2014
author/source: Sinensis

Sinensis Life Sciences B.V., Leiden, the Netherlands (“Sinensis”), announces today that it has acquired Spinnovation Holding B.V., Oss, the Netherlands (“Spinnovation”), a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market.

SinensisFinancial terms of the transaction were not disclosed.

The addition of Spinnovation expands and strengthens Sinensis’ chemical R&D group as in addition to NMR Spinnovation offers mass spectrometry (MS) and inductively coupled plasma (ICP) spectroscopy analyses to its customers.

Dr Ruud Santing, CEO of Sinensis, commented: “We are excited to add Spinnovation’s analytical equipment and many years of expertise to our existing portfolio of capillary electrophoresis (CE), UPLC-QToF-MS and UPLC-TQ-MS, all techniques that are becoming more and more important in working on therapeutic proteins, monoclonal antibodies and other biologicals. Moreover, we are pleased that through Spinnovation we get a footprint in the Pivot Park in Oss housing an increasing number of (bio)pharmaceutical companies requiring GMP analytical services.”

Dr Frederic Girard, CEO of Spinnovation, commented: “The strategic fit between Spinnovation and the Sinensis group of contract laboratories is excellent, a group with many years of experience in servicing the (bio)pharmaceutical market. We are confident that with the help of Sinensis we will get a GMP license from the Dutch Healthcare Inspectorate rather soon. This license and being a part of Sinensis also means that we can further anchor our commitment to deliver turn-key solutions to our clients from drug and process development to API and product release, and accelerate our growth and realise our ambitions faster.”

Spinnovation will continue to operate independently and Dr Girard will continue to lead it, reporting to Dr Santing.

more about sinensis




Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd




Media Partners